標(biāo)題: Titlebook: Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology; Scientific and Clini M. R. Nowrousian Book 20021st edition Springer-Verlag/W [打印本頁(yè)] 作者: Cyclone 時(shí)間: 2025-3-21 16:28
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology影響因子(影響力)
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology被引頻次
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology被引頻次學(xué)科排名
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology年度引用
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology年度引用學(xué)科排名
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology讀者反饋
書(shū)目名稱(chēng)Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology讀者反饋學(xué)科排名
作者: MELON 時(shí)間: 2025-3-21 22:20 作者: projectile 時(shí)間: 2025-3-22 03:01
Yvonne Brandbergth the server-side data portal components:.It is also possible to create your own custom network channel by implementing DataPortalClient.IDataPortalProxy on the client, and Server.IDataPortalServer on the server, just as was done in Chapter 4 to create the four proxy/host combinations listed above.作者: 莎草 時(shí)間: 2025-3-22 05:25 作者: Melanocytes 時(shí)間: 2025-3-22 10:33
Wolfgang Jelkmann M.D.Chapter 9, there are many ways to create a Web Forms interface, and the one I’ve created here is just one option among many..The key is that the business objects automatically enforce all business rules and provide business processing so that the UI doesn’t need to include any of that code. As you c作者: cacophony 時(shí)間: 2025-3-22 16:51
Anders ?sterborgth the server-side data portal components:.It is also possible to create your own custom network channel by implementing DataPortalClient.IDataPortalProxy on the client, and Server.IDataPortalServer on the server, just as was done in Chapter 4 to create the four proxy/host combinations listed above.作者: Isolate 時(shí)間: 2025-3-22 17:38
Mario CazzolaChapter 9, there are many ways to create a Web Forms interface, and the one I’ve created here is just one option among many..The key is that the business objects automatically enforce all business rules and provide business processing so that the UI doesn’t need to include any of that code. As you c作者: Defiance 時(shí)間: 2025-3-23 00:21
M. R. Nowrousianth the server-side data portal components:.It is also possible to create your own custom network channel by implementing DataPortalClient.IDataPortalProxy on the client, and Server.IDataPortalServer on the server, just as was done in Chapter 4 to create the four proxy/host combinations listed above.作者: allergen 時(shí)間: 2025-3-23 04:56 作者: 相互影響 時(shí)間: 2025-3-23 08:45 作者: neutrophils 時(shí)間: 2025-3-23 12:32 作者: 不適當(dāng) 時(shí)間: 2025-3-23 15:54
Relationship between anemia and tumor hypoxia, satisfy the oxygen demand (Vaupel et al. 1989). The complex pathophysiological mechanisms have recently been reviewed (H?ckel and Vaupel 2001). Hypoxia seems to represent a general pathophysiological phenomenon in solid cancers and is associated with more rapid malignant progression and poor prognosis (H?ckel et al. 1996; H?ckel and Vaupel 2001).作者: 財(cái)產(chǎn) 時(shí)間: 2025-3-23 20:49 作者: curettage 時(shí)間: 2025-3-24 02:16
M. R. NowrousianComprehensive presentation of anemia in cancer and its treatment.Assessment of current and potential applications of erythopoietin.Presented by world experts in the field作者: Vldl379 時(shí)間: 2025-3-24 03:56
Prevalence, pathophysiology, predictive factors, and prognostic significance of anemia in cancer chusually worsens during radiotherapy and chemotherapy, and in a considerable number of patients, radiotherapy and chemotherapy as such produce anemia, primarily due to their myelosuppressive effect (Tables 1–3) (Skillings et al. 1993; Estrin et al. 1999; Groopman and Itri 1999; Lammering et al. 1999;作者: 遭遇 時(shí)間: 2025-3-24 07:55
Red blood cell transfusion, risks and limitations,ll be undetectable even with the most sensitive screening tests. Moreover it is necessary to define, together with the risk of transfusion transmitted infections, the nature and magnitude of all the other potential risk of blood transfusion such as the immunological risks and circulatory and metabol作者: 后退 時(shí)間: 2025-3-24 12:22 作者: 你不公正 時(shí)間: 2025-3-24 18:41
rhEPO in anemia associated with solid tumors and chemotherapy, multiple transfusions (Barrett-Lee et al. 2000). The mean proportion of patients with Hb levels less than 11 g/dl rose from 17% before the first cycle, to 38% by the sixth, despite the transfusions in 33% of patients. In a recent comprehensive review of chemotherapy trials, the incidence of anemia 作者: 不來(lái) 時(shí)間: 2025-3-24 19:31 作者: 老巫婆 時(shí)間: 2025-3-25 02:15
rhEPO in hematopoietic stem cell mobilization, transplantation and in-vitro expansion,hEPO) has been established as a treatment for renal anemia it has been of interest whether treatment may be of benefit in the transplantation setting. So far data do . support any transfusional benefits with the use of rhEPO after autologous transplantation. In patients receiving an allograft, espec作者: Keshan-disease 時(shí)間: 2025-3-25 04:28 作者: 浮雕 時(shí)間: 2025-3-25 10:40
Book 20021st editione rhEPO. The book will serve as an authentic and essential source of information for radiotherapists, oncologists, hematologists, internists, pediatricians, surgeons, specialists in transfusion or laboratory medicine and pharmacologists.作者: 看法等 時(shí)間: 2025-3-25 14:37 作者: 愛(ài)得痛了 時(shí)間: 2025-3-25 16:40
M. R. Nowrousianse security by running the data portal server components on a separate application server. In either case, all you need to do is change some settings in Web.config; the UI code and business objects will work in all these scenarios..In Chapter 11, I?ll show how you can create another type of interfac作者: Mangle 時(shí)間: 2025-3-25 23:30
Yvonne Brandberg objects will support data binding in Windows Forms and Web Forms, along with support for encapsulation of validation and authorization logic in a clear and concise manner..I’ve thoroughly enjoyed exploring these concepts with you, and wish you the best as you develop your software..Code well, have 作者: N防腐劑 時(shí)間: 2025-3-26 00:14 作者: spinal-stenosis 時(shí)間: 2025-3-26 05:30
Wolfgang Jelkmann M.D.se security by running the data portal server components on a separate application server. In either case, all you need to do is change some settings in Web.config; the UI code and business objects will work in all these scenarios..In Chapter 11, I?ll show how you can create another type of interfac作者: 憂(yōu)傷 時(shí)間: 2025-3-26 11:18 作者: Foreshadow 時(shí)間: 2025-3-26 14:56 作者: 射手座 時(shí)間: 2025-3-26 19:48
M. R. Nowrousian objects will support data binding in Windows Forms and Web Forms, along with support for encapsulation of validation and authorization logic in a clear and concise manner..I’ve thoroughly enjoyed exploring these concepts with you, and wish you the best as you develop your software..Code well, have 作者: rectum 時(shí)間: 2025-3-26 22:27
Recombinant Human Erythropoietin (rhEPO) in Clinical OncologyScientific and Clini作者: cylinder 時(shí)間: 2025-3-27 04:11
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology978-3-7091-7658-0作者: chalice 時(shí)間: 2025-3-27 06:12 作者: 植物茂盛 時(shí)間: 2025-3-27 11:34
Use of recombinant human erythropoietin in the treatment of myelodysplastic syndromes,kemia. Although the clinical course of these disorders is highly variable from patient to patient, the International Prognostic Scoring System (Greenberg et al. 1997) provides an improved method for evaluating prognosis in individual MDS patients (Sanz et al. 1998).作者: hallow 時(shí)間: 2025-3-27 14:54
Pathophysiology of cancer-related anemia, 1983; Zucker 1985; Kreuzer et al. 1997; Tiziana and Caligaris-Cappio 1997; Voulgari et al. 1999). This type of anemia, referred to as the anemia of chronic disease (ACD), accounts for 52% of anemias in patients without blood loss, hemolysis or hematologic malignancies. In 19% of cases with ACD, cancer is the cause of anemia (Cash and Sears 1989).作者: 小臼 時(shí)間: 2025-3-27 19:24
Incidence and impact of anemia in radiation oncology,ined and most radiotherapists did not focus on the prognostic impact of anemia in daily work. The main question over the recent years has concentrated on whether or not the well-known association between anemia and survival reflects a causal relationship or represents only an epiphenomemon (Fyles et al. 2000).作者: bronchiole 時(shí)間: 2025-3-28 00:54
Book 20021st editionously thought. Beyond clinical symptoms, anemia significantly impairs physical and metabolic functions as well as patients‘ activity, well-being and quality of life. Life expectancy is also affected. In this book, written by a group of outstanding international experts, the current knowledge on anem作者: considerable 時(shí)間: 2025-3-28 05:45
Biology of erythropoietin,(EpoR) and the Epo-induced intracellular signaling events. Finally, we will describe other compounds and mechanisms which mimic Epo action, thereby also leading to intracellular signalling albeit with a decreased efficiency when compared to Epo.作者: 草率女 時(shí)間: 2025-3-28 07:53
Classification and characterization of anemia in cancer,y adults, hemoglobin levels range between 13.3–17.7 g/dl in men and 11.7–15.7 g/dl in women (Williams 1988; Fairbanks and Tefferi 2000). According to the World Health Organization, values below 13 g/dl in men and 12 g/dl in women are defined as anemia (World Health Organization 1968).作者: AXIOM 時(shí)間: 2025-3-28 13:21 作者: 向前變橢圓 時(shí)間: 2025-3-28 18:18
rhEPO in pediatric oncology, growth factors have been used to reduce the degree and duration of chemotherapy-induced myelosuppression, the main adverse effect of chemotherapy (Furman 1992; Trillet-Lenoir et al. 1993; Burdach et al. 1995; Riikonen et al. 1995; Mitchell et al. 1997; Rahiala et al. 1999).作者: 我要威脅 時(shí)間: 2025-3-28 21:56 作者: 怕失去錢(qián) 時(shí)間: 2025-3-29 01:19 作者: CRUDE 時(shí)間: 2025-3-29 05:47
Clinical trials using rhEPO in radiation oncology,of which may be an impaired oxygen-dependent radiosensitivity (Becker et al. 2000; Henke et al. 2000b) — the oxygen-effect (Gray et al. 1953). Thus, it is hoped that the correction of the anemic state of these patients can improve tumor oxygenation and, eventually, cancer cure.作者: TOM 時(shí)間: 2025-3-29 08:27
by world experts in the fieldAnemia is a frequent complication of cancer and its treatment. A number of clinical studies shows that the impact of anemia is much greater than previously thought. Beyond clinical symptoms, anemia significantly impairs physical and metabolic functions as well as patien作者: 神經(jīng) 時(shí)間: 2025-3-29 11:48 作者: Contort 時(shí)間: 2025-3-29 16:21 作者: abduction 時(shí)間: 2025-3-29 20:40 作者: 賞錢(qián) 時(shí)間: 2025-3-30 02:16 作者: 冥界三河 時(shí)間: 2025-3-30 05:05 作者: 賞心悅目 時(shí)間: 2025-3-30 08:39
Relationship between anemia and tumor hypoxia, satisfy the oxygen demand (Vaupel et al. 1989). The complex pathophysiological mechanisms have recently been reviewed (H?ckel and Vaupel 2001). Hypoxia seems to represent a general pathophysiological phenomenon in solid cancers and is associated with more rapid malignant progression and poor progno作者: expire 時(shí)間: 2025-3-30 13:52
Tumor hypoxia and therapeutic resistance,e to the lack of methods suitable for the routine measurement of intratumoral oxygen tensions in patients. In the late 1980s, a novel and clinically applicable standardized procedure was established enabling the determination of tumor oxygenation in accessible primary tumors, local recurrences, and 作者: 生命 時(shí)間: 2025-3-30 20:24 作者: Albinism 時(shí)間: 2025-3-30 22:39
Relationship between anemia, fatigue, and quality of life in cancer patients,anced stages of cancer (Groopman and Itri 2000; Khayat 2000). The clinical symptoms of anemia, such as fatigue, dyspnoea, vertigo, loss of appetite, and inability to concentrate impair the patients physical functioning and subjective sense of well-being (Groopman and Itri 2000). By relieving these s作者: GOUGE 時(shí)間: 2025-3-31 03:42
Red blood cell transfusion, risks and limitations, tissues induced by surgical related anemia, but it is now perceived as a procedure to be avoided. The safety of blood supply has been in question since the first cases of transfusion transmitted AIDS in the early 1980. In response to this crisis blood collection centres implemented a successful mul作者: Metamorphosis 時(shí)間: 2025-3-31 05:56
Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin (rhEPO),enation is the primary determinant of the expression of the EPO gene in the kidney. Other production sites contribute little to circulating EPO in humans after birth, albeit the liver is the main site of EPO mRNA expression in fetuses. EPO inhibits the programmed cell death (apoptosis) of the erythr作者: DIS 時(shí)間: 2025-3-31 09:57
Recombinant human erythropoietin (rhEPO) in anemia associated with multiple myeloma and non-Hodgkin manifested at the time of diagnosis. In patients with MM, hemoglobin values <10.0g/dL were found in 49% and severe anemia (hemoglobin <7.5 g/dL) in 19% of the patients already at the time of diagnosis (MRC working party 1980). Patients with NHL have been reported to have an anemia rate of approxima作者: Lamina 時(shí)間: 2025-3-31 16:32 作者: 小卷發(fā) 時(shí)間: 2025-3-31 20:07 作者: enlist 時(shí)間: 2025-3-31 22:08 作者: embolus 時(shí)間: 2025-4-1 03:07 作者: fatuity 時(shí)間: 2025-4-1 09:17
Clinical trials using rhEPO in radiation oncology, cytokine stimulates the autologous erythropoiesis (Graber et al. 1978; Gregory et al. 1978) and can efficiently correct anemia in cancer patients (Abels et al. 1993; Dusenbery et al. 1994; Henke et al. 1999a; Lavey et al. 1993; Ludwig et al. 1990; Sweeney et al. 1998; Oster et al. 1990). Poor tumor作者: 閑逛 時(shí)間: 2025-4-1 13:39
rhEPO in pediatric oncology,djuvant, long-term, etc.), and radiotherapy (fractionated, local therapy, plaque therapy, high dosage, etc). For many years, recombinant hematopoietic growth factors have been used to reduce the degree and duration of chemotherapy-induced myelosuppression, the main adverse effect of chemotherapy (Fu作者: CRACY 時(shí)間: 2025-4-1 14:42
rHuEPO in surgical oncology, last decade and allogeneic blood supply can be currently considered safer than ever in the history of blood transfusion, allogeneic blood transfusion is still viewed as an outcome that, whenever possible, should be avoided.作者: 離開(kāi)可分裂 時(shí)間: 2025-4-1 21:32
Textbook 2018nce. The first book to introduce pathwise formulae for the stochastic integral, it provides a simple but rigorous treatment of the subject, including a range of advanced topics. The book discusses in-depth topics such as quadratic variation, Ito formula, and Emery topology. The authors briefly addre作者: Criteria 時(shí)間: 2025-4-2 01:01 作者: 致詞 時(shí)間: 2025-4-2 06:34
